

William D Figg

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5207826/william-d-figg-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

649
papers

28,592
citations

90
h-index

148
g-index

686
ext. papers

32,017
ext. citations

5.9
avg, IF

6.81
L-index

#	Paper	IF	Citations
649	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1148-59	2.2	1651
648	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3461-7	2.2	839
647	Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5410-7	2.2	601
646	Thalidomide. <i>Lancet, The</i> , 2004 , 363, 1802-11	4.0	434
645	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 66, 545-551	13.4	407
644	Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 74-82	2.2	394
643	Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). <i>Clinical Cancer Research</i> , 2005 , 11, 4136-43	12.9	380
642	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 708-15	2.2	377
641	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011 , 117, 5827-34	2.2	368
640	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. <i>Clinical Cancer Research</i> , 2002 , 8, 718-28	12.9	353
639	Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3912-22	2.2	351
638	Angiogenesis inhibitors: current strategies and future prospects. <i>Ca-A Cancer Journal for Clinicians</i> , 2010 , 60, 222-43	220.7	350
637	Herbal remedies in the United States: potential adverse interactions with anticancer agents. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2489-503	2.2	346
636	Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2532-9	2.2	276
635	Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2319-33	2.2	274
634	Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. <i>Biochemical Pharmacology</i> , 1998 , 55, 1827-34	6	266
633	Activity of thalidomide in AIDS-related Kaposi's sarcoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2593-602.	2.2	261

632	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. <i>Blood</i> , 2007 , 109, 2781-90	2.2	253
631	Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. <i>Clinical Cancer Research</i> , 2007 , 13, 5183-94	12.9	250
630	Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 15-25	9.7	233
629	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015 , 1, 746-54	13.4	224
628	Drug interactions in cancer therapy. <i>Nature Reviews Cancer</i> , 2006 , 6, 546-58	31.3	224
627	Rational development of histone deacetylase inhibitors as anticancer agents: a review. <i>Molecular Pharmacology</i> , 2005 , 68, 917-32	4.3	205
626	Antibody-drug conjugates for cancer. <i>Lancet, The</i> , 2019 , 394, 793-804	40	204
625	Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. <i>Clinical Cancer Research</i> , 2006 , 12, 5777-85	12.9	191
624	Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. <i>Clinical Cancer Research</i> , 2011 , 17, 907-17	12.9	188
623	Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. <i>Current Neuropharmacology</i> , 2006 , 4, 165-72	7.6	185
622	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <i>Drug Resistance Updates</i> , 2003 , 6, 71-84	23.2	181
621	Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. <i>Cancer Biology and Therapy</i> , 2005 , 4, 815-8	4.6	181
620	Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 8573-8	11.5	178
619	Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. <i>Clinical Cancer Research</i> , 2008 , 14, 4200-5	12.9	177
618	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 997-1008	3.5	175
617	Validation of analytic methods for biomarkers used in drug development. <i>Clinical Cancer Research</i> , 2008 , 14, 5967-76	12.9	174
616	A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. <i>Journal of Experimental Therapeutics and Oncology</i> , 2002 , 2, 325-32	0.8	170
615	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020 , 382, 1430-1442	59.2	163

614	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2193-2202	2.2	159
613	Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 3312-8	12.9	155
612	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2299-304	2.2	154
611	A phase II clinical trial of sorafenib in androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 209-14	12.9	151
610	Scientific collaboration results in higher citation rates of published articles. <i>Pharmacotherapy</i> , 2006 , 26, 759-67	5.8	149
609	Pharmacogenetics of irinotecan metabolism and transport: an update. <i>Toxicology in Vitro</i> , 2006 , 20, 163-75	7.5	146
608	Effect of ABCG2 genotype on the oral bioavailability of topotecan. <i>Cancer Biology and Therapy</i> , 2005 , 4, 650-8	4.6	144
607	A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 4820-9	12.9	141
606	Molecular alterations in primary prostate cancer after androgen ablation therapy. <i>Clinical Cancer Research</i> , 2005 , 11, 6823-34	12.9	141
605	The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2496-508	6.1	139
604	Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju089	9.7	135
603	Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. <i>European Journal of Cancer</i> , 2006 , 42, 2893-6	7.5	135
602	Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E1083-91	11.5	134
601	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2565-73	2.2	134
600	Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2807-13	4.3	131
599	Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. <i>Journal of Biological Chemistry</i> , 2009 , 284, 26831-8	5.4	130
598	A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 2344-51	12.9	128
597	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. <i>Blood</i> , 2011 , 117, 4787-95	2.2	127

596	Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 584-92	2.2	127
595	Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2070-6	2.2	126
594	Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. <i>Molecular Cancer Research</i> , 2006 , 4, 135-50	6.6	126
593	Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 153-9	2.2	123
592	A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 569-80	12.9	122
591	Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. <i>Cancer Research</i> , 2008 , 68, 9996-10003	10.1	122
590	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. <i>Cancer Biology and Therapy</i> , 2006 , 5, 22-7	4.6	119
589	Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 1411-6	12.9	118
588	ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. <i>Clinical Cancer Research</i> , 2008 , 14, 4543-9	12.9	117
587	Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4074-82	2.2	116
586	Thalidomide metabolism by the CYP2C subfamily. <i>Clinical Cancer Research</i> , 2002 , 8, 1964-73	12.9	114
585	The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. <i>Journal of Surgical Research</i> , 2000 , 91, 26-31	2.5	113
584	Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. <i>Annals of Pharmacotherapy</i> , 2002 , 36, 905-11	2.9	112
583	Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005 , 1, 429-45	5.5	111
582	Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. <i>Drug Resistance Updates</i> , 2004 , 7, 195-208	23.2	111
581	Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2002 , 8, 963-70	12.9	108
580	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 1-8	1.9	107
579	Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. <i>Clinical Cancer Research</i> , 2007 , 13, 5411-7	12.9	107

578	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. <i>European Urology</i> , 2008 , 54, 1089-94	10.2	106
577	Clinical and molecular responses in lung cancer patients receiving Romidepsin. <i>Clinical Cancer Research</i> , 2008 , 14, 188-98	12.9	106
576	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 192-201	6.1	105
575	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. <i>Seminars in Oncology</i> , 2001 , 28, 62-66	5.5	104
574	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2009 , 103, 1636-40	5.6	102
573	Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. <i>Cancer Investigation</i> , 2009 , 27, 221-6	2.1	102
572	Phase I study of phenylacetate administered twice daily to patients with cancer. <i>Cancer</i> , 1995 , 75, 2932-8	6.4	101
571	Population pharmacokinetic analysis of sorafenib in patients with solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 294-305	3.8	100
570	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. <i>Pharmacogenomics</i> , 2005 , 6, 115-38	2.6	100
569	TNP-470: an angiogenesis inhibitor in clinical development for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 1383-96	5.9	100
568	Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1585-92	9.7	98
567	Multiparametric MRI in prostate cancer management. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 346-53	19.4	97
566	A working group classification of focal prostate atrophy lesions. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 1281-91	6.7	97
565	A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. <i>Clinical Cancer Research</i> , 2011 , 17, 6831-9	12.9	96
564	Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 854-60	2.9	95
563	Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. <i>Clinical Cancer Research</i> , 2012 , 18, 2099-107	12.9	94
562	Modulation of cytochrome P450 activity: implications for cancer therapy. <i>Lancet Oncology</i> , 2005 , 6, 780-9	21.7	94
561	Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3465-74	2.2	93

560	Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. <i>Journal of Urology</i> , 2008 , 179, 2181-5; discussion 2185-6	2.5	91
559	Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1 α in advanced solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 5123-31	12.9	90
558	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1389-1395	2.2	89
557	Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. <i>PLoS ONE</i> , 2011 , 6, e14504	3.7	88
556	A phase II study of perifosine in androgen independent prostate cancer. <i>Cancer Biology and Therapy</i> , 2005 , 4, 1133-7	4.6	88
555	A retrospective study of the time to clinical endpoints for advanced prostate cancer. <i>BJU International</i> , 2005 , 96, 985-9	5.6	88
554	Pharmacokinetics of thalidomide in an elderly prostate cancer population. <i>Journal of Pharmaceutical Sciences</i> , 1999 , 88, 121-5	3.9	87
553	Pharmacogenetics of membrane transporters: an update on current approaches. <i>Molecular Biotechnology</i> , 2010 , 44, 152-67	3	86
552	Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. <i>Journal of Clinical Oncology</i> , 2001 , 19, 832-42	2.2	86
551	Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3599-604	2.2	86
550	Review of UCN-01 development: a lesson in the importance of clinical pharmacology. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 394-403	2.9	83
549	Expression of OATP family members in hormone-related cancers: potential markers of progression. <i>PLoS ONE</i> , 2011 , 6, e20372	3.7	81
548	Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. <i>Microvascular Research</i> , 2000 , 60, 70-80	3.7	81
547	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 95	12.8	77
546	Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 499-506	2.2	77
545	Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 268, 183-91	3.4	77
544	Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. <i>Urology</i> , 1998 , 52, 252-6	1.6	77
543	Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. <i>American Journal of Medicine</i> , 1995 , 98, 412-4	2.4	77

542	Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. <i>Investigational New Drugs</i> , 2002 , 20, 183-94	4.3	75
541	CYP2D6 polymorphisms and the impact on tamoxifen therapy. <i>Journal of Pharmaceutical Sciences</i> , 2007 , 96, 2224-31	3.9	74
540	Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 42 Suppl, S54-9	3.5	72
539	A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. <i>Clinical Cancer Research</i> , 2014 , 20, 5392-402	12.9	71
538	Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 19-26	6.1	70
537	Relationship of systemic exposure to unbound docetaxel and neutropenia. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 43-53	6.1	68
536	A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valsopodar). <i>Cancer</i> , 2001 , 92, 1577-90	6.4	68
535	Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. <i>Cancer Biology and Therapy</i> , 2005 , 4, 1222-5	4.6	67
534	Influence of garlic (<i>Allium sativum</i>) on the pharmacokinetics of docetaxel. <i>Clinical Cancer Research</i> , 2006 , 12, 4636-40	12.9	66
533	Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4356-63	2.2	66
532	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 148, 256-67	4.5	65
531	Thalidomide metabolism and hydrolysis: mechanisms and implications. <i>Current Drug Metabolism</i> , 2006 , 7, 677-85	3.5	65
530	Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. <i>Cancer Research</i> , 2004 , 64, 821-4	10.1	64
529	Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. <i>Clinical Cancer Research</i> , 2006 , 12, 4331-8	12.9	63
528	Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. <i>Nature Communications</i> , 2018 , 9, 2705	17.4	62
527	Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 5038-47	12.9	62
526	A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valsopodar (PSC 833) in renal cell carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 4724-33	12.9	62
525	Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. <i>Pharmacogenomics</i> , 2010 , 11, 89-103	2.6	61

524	A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 7101-6	12.9	61
523	Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. <i>Cancer Research</i> , 2003 , 63, 3189-94	10.1	61
522	Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. <i>Clinical Cancer Research</i> , 2005 , 11, 7398-404	12.9	60
521	Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. <i>Cancer</i> , 1995 , 76, 453-62	6.4	60
520	Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. <i>Annals of Pharmacotherapy</i> , 1997 , 31, 76-82	2.9	58
519	Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. <i>Cancer</i> , 2016 , 122, 588-597	6.4	57
518	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. <i>Clinical Cancer Research</i> , 2009 , 15, 1496-503	12.9	57
517	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. <i>BJU International</i> , 2008 , 102, 617-21	5.6	57
516	Suramin's development: what did we learn?. <i>Investigational New Drugs</i> , 2002 , 20, 209-19	4.3	57
515	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 1484-1499	2.9	57
514	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4125-4131	2.2	57
513	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4633-4641	12.9	56
512	Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. <i>Cancer Biology and Therapy</i> , 2002 , 1, 669-73	4.6	56
511	Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. <i>Therapeutics and Clinical Risk Management</i> , 2005 , 1, 107-14	2.9	55
510	Thalidomide analogues as anticancer drugs. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007 , 2, 167-74.6	4.6	55
509	Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. <i>American Journal of Cardiology</i> , 1995 , 76, 1072-3	3	54
508	Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. <i>American Journal of Medicine</i> , 1988 , 85, 452-3	2.4	54
507	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 599-608	7.4	53

506	COVID-19 Clinical Diagnostics and Testing Technology. <i>Pharmacotherapy</i> , 2020 , 40, 857-868	5.8	53
505	Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1 β /p300 complex in a preclinical model of prostate cancer. <i>Molecular Cancer</i> , 2014 , 13, 91	42.1	52
504	Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 800-11	2.2	52
503	A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses 2019 , 7, 197		51
502	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. <i>Clinical Immunology</i> , 2014 , 155, 176-87	9	51
501	Phase I trial of a new schedule of romidepsin in patients with advanced cancers. <i>Clinical Cancer Research</i> , 2013 , 19, 4499-507	12.9	51
500	An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5918-26	12.9	50
499	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 299-307	7.4	50
498	Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. <i>Anti-Cancer Drugs</i> , 2007 , 18, 111-26	2.4	50
497	Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF α -modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 3793-9	8.3	50
496	Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008 , 46, 362-7	3.5	49
495	Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E1724-33	11.5	48
494	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. <i>Clinical Cancer Research</i> , 2019 , 25, 4945-4954	12.9	47
493	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 12703-8	11.5	47
492	Integrating pharmacogenetic information and clinical decision support into the electronic health record. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014 , 21, 522-8	8.6	46
491	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik β mAb in patients with T-cell large granular lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 476-84	2.2	46
490	Laparoscopic continuous hyperthermic peritoneal perfusion. <i>Journal of the American College of Surgeons</i> , 2001 , 193, 225-9	4.4	46
489	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015 , 116, 546-55	5.6	45

488	Phase I study of oral lenalidomide in patients with refractory metastatic cancer. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 650-60	2.9	45
487	Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. <i>Clinical Cancer Research</i> , 2011 , 17, 3388-97	12.9	45
486	Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. <i>Clinical Cancer Research</i> , 2004 , 10, 4192-7	12.9	45
485	Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 862, 213-8	3.2	44
484	Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 2219-27	8.3	44
483	The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. <i>Clinical Cancer Research</i> , 2002 , 8, 1242-50	12.9	44
482	Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. <i>Cancer Investigation</i> , 1996 , 14, 513-7	2.1	43
481	Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 796, 181-8	3.2	43
480	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 645-652	3.5	42
479	A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012 , 880, 132-9	3.2	42
478	5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 104-10	3.2	42
477	Dual targeting of the androgen receptor and hypoxia-inducible factor 1 pathways synergistically inhibits castration-resistant prostate cancer cells. <i>Molecular Pharmacology</i> , 2015 , 87, 1006-12	4.3	41
476	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , 2007 , 99, 1047-55	5.6	41
475	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019 , 69, 2048-2060	11.2	41
474	Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 4292-8	12.9	40
473	Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates. <i>ELife</i> , 2019 , 8,	8.9	40
472	Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. <i>International Journal of Cancer</i> , 2016 , 139, 1648-57	7.5	40
471	Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1083-90	4.7	39

470	Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. <i>Clinical Cancer Research</i> , 2013 , 19, 3095-104	12.9	39
469	Recent advances in pharmacogenetic approaches to anticancer drug development. <i>Drug Development Research</i> , 2004 , 62, 233-253	5.1	39
468	Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. <i>Annals of Pharmacotherapy</i> , 2003 , 37, 1369-74	2.9	39
467	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2013 , 111, 1269-80	5.6	38
466	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , 2010 , 10, 511	4.8	38
465	Approaches to preclinical screening of antiangiogenic agents. <i>Seminars in Oncology</i> , 2001 , 28, 570-6	5.5	38
464	Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. <i>Discovery Medicine</i> , 2012 , 13, 19-34	2.5	38
463	Reversal of Multidrug Resistance: Lessons from Clinical Oncology. <i>Novartis Foundation Symposium</i> , 83-102		38
462	TMPRSS2: Potential Biomarker for COVID-19 Outcomes. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 801-807	2.9	38
461	Statin drug use is not associated with prostate cancer risk in men who are regularly screened. <i>Journal of Urology</i> , 2014 , 192, 379-84	2.5	37
460	Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 368-73	2.9	37
459	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3672-3684 ^{2.2}		37
458	Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. <i>Journal of Controlled Release</i> , 2017 , 268, 147-158	11.7	36
457	The effect of an adenosine A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. <i>Fluids and Barriers of the CNS</i> , 2018 , 15, 2	7	36
456	Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1698-705	9.7	36
455	Methods for extracting and amplifying genomic DNA isolated from frozen serum. <i>Nature Biotechnology</i> , 1998 , 16, 91-4	44.5	36
454	Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. <i>Human Gene Therapy</i> , 1999 , 10, 889-98	4.8	36
453	A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 1995 , 75, 2159-64	6.4	36

452	Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. <i>Cancer Causes and Control</i> , 2011 , 22, 1121-31	2.8	35
451	Disclosing a diagnosis of cancer: where and how does it occur?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3630-5	2.2	35
450	Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 275-81	3.5	35
449	Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002 , 123, 686-94	1.5	35
448	Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. <i>Journal of Urology</i> , 2010 , 184, 2297-302	2.5	34
447	New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. <i>Angiogenesis</i> , 1997 , 1, 23-35	10.6	34
446	Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 394-401	2.9	34
445	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 77-85	3.3	33
444	A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. <i>United European Gastroenterology Journal</i> , 2015 , 3, 453-61	5.3	33
443	A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. <i>Journal of Urology</i> , 2009 , 181, 1104-13; discussion 1113	2.5	33
442	EFFICACY OF MICROTUBULE-ACTIVE DRUGS FOLLOWED BY KETOCONAZOLE IN HUMAN METASTATIC PROSTATE CANCER CELL LINES. <i>Journal of Urology</i> , 2000 , 163, 1022-1026	2.5	33
441	Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1397-1406	12.9	32
440	Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 368-81	6.2	32
439	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3333-3340	15.9	32
438	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 1099-1109	21.7	31
437	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017 , 1, 1911-1918	7.8	31
436	A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. <i>Therapeutics and Clinical Risk Management</i> , 2010 , 6, 579-83	2.9	31
435	Synthesis of racemic cis-5-hydroxy-3-phthalimidoglutaramide. A metabolite of thalidomide isolated from human plasma. <i>Journal of Organic Chemistry</i> , 2005 , 70, 10117-20	4.2	31

434	A facile scheme for phthalimide to phthalimidine conversion. <i>Tetrahedron Letters</i> , 1999 , 40, 2087-2090	2	31
433	Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1 α /p300 Interaction. <i>Journal of Natural Products</i> , 2016 , 79, 1267-75	4.9	31
432	Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. <i>Cancer</i> , 2006 , 106, 63-7	6.4	30
431	Pharmacokinetics of ondansetron in patients with hepatic insufficiency. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 206-15	2.9	30
430	Androgen receptor variation affects prostate cancer progression and drug resistance. <i>Pharmacological Research</i> , 2016 , 114, 152-162	10.2	30
429	Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1 α . <i>Journal of the American Chemical Society</i> , 2015 , 137, 5569-75	16.4	29
428	Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. <i>Cancer Biology and Therapy</i> , 2010 , 10, 13-8	4.6	29
427	Angiogenesis inhibitors in the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 233-47	4	29
426	Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. <i>Human Reproduction</i> , 2003 , 18, 1820-7	5.7	29
425	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2326-2338	15.9	29
424	In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. <i>Oncotarget</i> , 2016 , 7, 33237-45	3.3	29
423	Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models. <i>Cancer Biology and Therapy</i> , 2010 , 10, 38-43	4.6	28
422	Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 79175-79187	3.3	28
421	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. <i>Anti-Cancer Drugs</i> , 2018 , 29, 457-465	2.4	27
420	Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. <i>Scientific Reports</i> , 2016 , 6, 30038	4.9	27
419	Inhibition of the HIF1 α /p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). <i>European Journal of Medicinal Chemistry</i> , 2015 , 94, 509-16	6.8	27
418	A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. <i>Journal of Urology</i> , 2010 , 183, 2219-26	2.5	27
417	Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1246-50	6.1	27

416	Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1004-5	4.6	27
415	Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 806, 305-10	3.2	27
414	Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 62, 140-8	3.5	26
413	Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. <i>Journal of Pharmaceutical Sciences</i> , 2007 , 96, 1821-31	3.9	26
412	Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. <i>Clinical Cancer Research</i> , 2004 , 10, 6840-6	12.9	26
411	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. <i>Oncotarget</i> , 2014 , 5, 8161-72	3.3	26
410	Are sex discordant outcomes in COVID-19 related to sex hormones?. <i>Seminars in Oncology</i> , 2020 , 47, 335-340	5.5	26
409	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 461-73	2.9	26
408	Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2228-37	6.1	25
407	Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold. <i>Journal of Organic Chemistry</i> , 2016 , 81, 10631-10640	4.2	25
406	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. <i>Journal of Clinical Pharmacology</i> , 2014 , 54, 865-73	2.9	25
405	The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011 , 708, 21-7	3.3	25
404	Selective leukemic-cell killing by a novel functional class of thalidomide analogs. <i>Blood</i> , 2006 , 108, 4126-35		25
403	UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. <i>Invasion & Metastasis</i> , 1998 , 18, 209-18		25
402	Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43 Suppl, S78-84	3.5	25
401	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1781-1783	13.4	25
400	A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 154-61	3.8	24
399	Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. <i>Cancer Prevention Research</i> , 2013 , 6, 91-9	3.2	24

398	Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. <i>Urology</i> , 2007 , 70, 217-20	1.6	24
397	A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. <i>Clinical Prostate Cancer</i> , 2004 , 2, 241-3		24
396	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021 , 39, 566-579.e7	24.3	24
395	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 406-410	6.2	24
394	ANG1005 for breast cancer brain metastases: correlation between F-FLT-PET after first cycle and MRI in response assessment. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 51-59	4.4	23
393	A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013 , 31, 714-23	4.3	23
392	Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. <i>Clinical Cancer Research</i> , 2014 , 20, 5652-62	12.9	23
391	Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment. <i>Cancer Biology and Therapy</i> , 2013 , 14, 90-1	4.6	23
390	Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E368-72	5.6	23
389	Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. <i>Anti-Cancer Drugs</i> , 2003 , 14, 125-35	2.4	23
388	Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. <i>Cancer Biology and Therapy</i> , 2002 , 1, 420-5	4.6	23
387	Acute renal toxicity associated with suramin in the treatment of prostate cancer. <i>Cancer</i> , 1994 , 74, 1612-4	6.4	23
386	Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. <i>PLoS ONE</i> , 2015 , 10, e0126672	3.7	23
385	Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 643-655	4.5	23
384	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1694-1704	6.1	22
383	Using Epigenetic Therapy to Overcome Chemotherapy Resistance. <i>Anticancer Research</i> , 2016 , 36, 1-4	2.3	22
382	Pharmacogenetics of estrogen metabolism and transport in relation to cancer. <i>Current Drug Metabolism</i> , 2003 , 4, 505-13	3.5	22
381	Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. <i>Clinical Cancer Research</i> , 2003 , 9, 562-70	12.9	22

380	Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. <i>Clinical Cancer Research</i> , 2016 , 22, 1197-210	12.9	21
379	Pharmacogenomics and histone deacetylase inhibitors. <i>Pharmacogenomics</i> , 2016 , 17, 1807-1815	2.6	21
378	BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1583-5	4.6	21
377	The role of MRI in prostate cancer active surveillance. <i>BioMed Research International</i> , 2014 , 2014, 203906		21
376	Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. <i>Oncologist</i> , 2012 , 17, 312-20	5.7	21
375	A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 383-9	3.5	21
374	Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. <i>BJU International</i> , 2008 , 101, 884-8	5.6	21
373	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. <i>BJU International</i> , 2008 , 102, 1694-9	5.6	21
372	Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. <i>Mayo Clinic Proceedings</i> , 1999 , 74, 137-45	6.4	21
371	Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. <i>Cancer Causes and Control</i> , 2016 , 27, 175-82	2.8	20
370	Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 229-37	3.3	20
369	CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015 , 5, 122	5.3	20
368	Lysyl oxidase (LOX) and hypoxia-induced metastases. <i>Cancer Biology and Therapy</i> , 2006 , 5, 909-11	4.6	20
367	Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 605-11	3.5	20
366	PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. <i>Oncologist</i> , 2021 , 26, e115-e129	5.7	20
365	Treatment options for androgen-independent prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2003 , 1, 49-57	0.6	20
364	Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016 , 118, 590-7	5.6	19
363	Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. <i>PLoS ONE</i> , 2014 , 9, e95532	3.7	19

362	Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. <i>Cancer Prevention Research</i> , 2010 , 3, 1523-33	3.2	19
361	Secondary hormonal therapy for prostate cancer: what lies on the horizon?. <i>BJU International</i> , 2008 , 101, 271-4	5.6	19
360	Histone deacetylase inhibitors are potent radiation protectants. <i>Cancer Biology and Therapy</i> , 2004 , 3, 612-3	4.6	19
359	Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. <i>American Journal of Hematology</i> , 2001 , 67, 51-3	7.1	19
358	A preliminary risk-benefit assessment of paclitaxel. <i>Drug Safety</i> , 1995 , 12, 196-208	5.1	19
357	A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 92, 63-8	3.5	18
356	Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 123-8	2.9	18
355	A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. <i>Analytica Chimica Acta</i> , 1997 , 339, 91-97	6.6	18
354	Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. <i>Anti-Cancer Drugs</i> , 2008 , 19, 275-81	2.4	18
353	Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. <i>Investigational New Drugs</i> , 2006 , 24, 367-75	4.3	18
352	The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. <i>Clinical Prostate Cancer</i> , 2003 , 2, 153-9		18
351	Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. <i>Biomedical Applications</i> , 2001 , 759, 247-57		18
350	High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000 , 22, 1003-14	3.5	18
349	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 828-836	12.9	18
348	Reviewing the role of healthy volunteer studies in drug development. <i>Journal of Translational Medicine</i> , 2018 , 16, 336	8.5	18
347	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e349-e360	3.8	17
346	Phase I trial of 7-hydroxystaurosporine and fludarabine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2284-92	1.9	17
345	ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. <i>Anti-Cancer Drugs</i> , 2007 , 18, 563-8	2.4	17

344	Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. <i>Cancer Biology and Therapy</i> , 2004 , 3, 503-4	4.6	17
343	Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. <i>PLoS ONE</i> , 2016 , 11, e0152007	3.7	17
342	Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 811, 135-41	3.2	17
341	Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 159-163	1.9	16
340	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. <i>Blood</i> , 2020 , 135, 2316-2319	2.2	16
339	Sarcosine as a potential prostate cancer biomarker and therapeutic target. <i>Cancer Biology and Therapy</i> , 2010 , 9, 341-2	4.6	16
338	The genetics of castration-resistant prostate cancer: what can the germline tell us?. <i>Clinical Cancer Research</i> , 2008 , 14, 4691-3	12.9	16
337	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003 , 169, 357-360	2.5	16
336	Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer. <i>Nature Reviews Urology</i> , 2005 , 2, 101-7		16
335	A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer. <i>Urologia Internationalis</i> , 1999 , 63, 120-5	1.9	16
334	Mifepristone: antineoplastic studies. <i>Clinical Obstetrics and Gynecology</i> , 1996 , 39, 498-505	1.7	16
333	Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. <i>Anticancer Research</i> , 2003 , 23, 3585-90	2.3	16
332	A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 955-67	3.5	15
331	Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease. <i>Cancer Biology and Therapy</i> , 2013 , 14, 1005-6	4.6	15
330	Impact of ABCB1 allelic variants on QTc interval prolongation. <i>Clinical Cancer Research</i> , 2011 , 17, 937-46	12.9	15
329	In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. <i>Cancer Letters</i> , 1997 , 113, 111-6	9.9	15
328	A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. <i>Acta Oncologica</i> , 2003 , 42, 195-201	3.2	15
327	Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 806, 289-93	3.2	15

326	The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. <i>Prostate</i> , 1996 , 29, 177-82	4.2	15
325	Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , 2021 , 18, 209-226	5.5	15
324	Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. <i>Molecular Cancer Therapeutics</i> , 2003 , 2, 845-54	6.1	15
323	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , 2017 , 22, 505-519	5.7	14
322	Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 603-10	3	14
321	Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. <i>Journal of Clinical Pharmacology</i> , 2017 , 57 Suppl 10, S67-S77	2.9	14
320	Monitor tumor burden with circulating tumor DNA. <i>Cancer Biology and Therapy</i> , 2013 , 14, 697-8	4.6	14
319	Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. <i>Annals of Pharmacotherapy</i> , 2010 , 44, 1709-17	2.9	14
318	Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. <i>Prostate</i> , 2010 , 70, 584-90	4.2	14
317	ETS-TMPRSS2 fusion gene products in prostate cancer. <i>Cancer Biology and Therapy</i> , 2006 , 5, 254-5	4.6	14
316	Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. <i>Clinical Cancer Research</i> , 2006 , 12, 3502-9	12.9	14
315	Angiogenesis and prostate cancer: important laboratory and clinical findings. <i>Current Oncology Reports</i> , 2005 , 7, 215-9	6.3	14
314	The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. <i>Urologia Internationalis</i> , 2002 , 68, 16-23	1.9	14
313	The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies. <i>Translational Cancer Research</i> , 2016 , 5, S1107-S1110	0.3	14
312	Pharmacogenetics of membrane transporters: a review of current approaches. <i>Methods in Molecular Biology</i> , 2014 , 1175, 91-120	1.4	14
311	Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. <i>Cancer</i> , 2016 , 122, 2332-40	6.4	14
310	Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. <i>Cytokine</i> , 2018 , 108, 213-224	4	14
309	Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters. <i>Molecular Pharmacology</i> , 2019 , 96, 158-167	4.3	13

308	UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 450-60	2.9	13
307	Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 446-56	11.2	13
306	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 31.e25-33	2.8	13
305	Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1586-7	4.6	13
304	Associations of serum sex steroid hormone and 5 α -androstane-3 α ,17 β -diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1823-32	4	13
303	Hormone-refractory prostate cancer: where are we going?. <i>Drugs</i> , 2007 , 67, 1109-24	12.1	13
302	Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. <i>European Urology</i> , 2007 , 52, 1020-7	10.2	13
301	Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. <i>Urology</i> , 2005 , 66, 571-6	1.6	13
300	Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. <i>Cancer Biology and Therapy</i> , 2004 , 3, 719-20	4.6	13
299	Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. <i>Expert Opinion on Therapeutic Patents</i> , 2004 , 14, 215-229	6.8	13
298	Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura. <i>Clinical Lung Cancer</i> , 2002 , 4, 186-92	4.9	13
297	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. <i>Biomedical Chromatography</i> , 2000 , 14, 338-43	1.7	13
296	Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 714-20	3.2	13
295	Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 10-9	3.3	12
294	More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer. <i>BJU International</i> , 2010 , 105, 913-6	5.6	12
293	Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis. <i>Journal of Chromatographic Science</i> , 2008 , 46, 356-61	1.4	12
292	The use of thalidomide in androgen-independent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 246-9	2.8	12
291	Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 804, 289-94	3.2	12

290	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. <i>Clinical Cancer Research</i> , 2020 , 26, 704-716	12.9	12
289	Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors. <i>ChemMedChem</i> , 2020 , 15, 270-273	3.7	12
288	Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models. <i>Marine Drugs</i> , 2018 , 16,	6	12
287	Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27820	3	11
286	A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application. <i>Chromatography (Basel)</i> , 2014 , 1, 82-95		11
285	Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 865, 153-8	3.2	11
284	Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 1124-35	2.9	11
283	Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. <i>World Journal of Urology</i> , 2004 , 22, 425-30	4	11
282	Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. <i>Southern Medical Journal</i> , 2015 , 108, 224-8	0.6	11
281	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020 , 126, 4936-4947	6.4	11
280	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. <i>Molecular Cancer Research</i> , 2017 , 15, 1096-1105	6.6	10
279	Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 401-407	4.8	10
278	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1769-1777	3.8	10
277	Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. <i>International Journal of Nanomedicine</i> , 2020 , 15, 991-1003	7.3	10
276	Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. <i>Carcinogenesis</i> , 2018 , 39, 125-133	4.6	10
275	Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. <i>Biomarkers in Medicine</i> , 2013 , 7, 831-41	2.3	10
274	CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents. <i>Cancer Biology and Therapy</i> , 2011 , 11, 549-51	4.6	10
273	Angiogenesis inhibitors increase tumor stem cells. <i>Cancer Biology and Therapy</i> , 2012 , 13, 586-7	4.6	10

272	Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. <i>Molecular Pharmacology</i> , 2008 , 74, 872-83	4.3	10
271	Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. <i>Cancer Biology and Therapy</i> , 2004 , 3, 1212-3	4.6	10
270	Immunomodulation of multiple myeloma. <i>Cancer Biology and Therapy</i> , 2004 , 3, 1060-1	4.6	10
269	Genotyping and functional analysis of the D104N variant of human endostatin. <i>Cancer Biology and Therapy</i> , 2004 , 3, 1298-303	4.6	10
268	Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 509-10	6.1	10
267	Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-hydroxyglutamic acid. <i>Tetrahedron Letters</i> , 2000 , 41, 2275-2278	2	10
266	Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2014 , 19, 16-24	1.6	10
265	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2019 , 25, 4238-4247	12.9	9
264	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1014-8	4.6	9
263	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF- α and angiogenesis inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 1547-1559	3.4	9
262	The ABCG2 Multidrug Transporter 2016 , 195-226		9
261	UGT genotyping in belinostat dosing. <i>Pharmacological Research</i> , 2016 , 105, 22-7	10.2	9
260	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. <i>International Journal of Cancer</i> , 2009 , 125, 1143-6	7.5	9
259	The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor. <i>Chemotherapy Research and Practice</i> , 2011 , 2011, 715469	0	9
258	Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). <i>Cancer Biology and Therapy</i> , 2005 , 4, 555-60	4.6	9
257	Cyclooxygenase-2 and angiogenesis in prostate cancer. <i>Cancer Biology and Therapy</i> , 2005 , 4, 813-4	4.6	9
256	Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. <i>Tetrahedron Letters</i> , 2000 , 41, 7151-7155	2	9
255	Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. <i>Cancer Treatment Reviews</i> , 1996 , 22, 105-18	14.4	9

254	Peripheral neuropathy in HIV patient after isoniazid therapy initiated. <i>DICP: the Annals of Pharmacotherapy</i> , 1991 , 25, 100-1		9
253	Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities. <i>Blood</i> , 2014 , 124, 2105-2105	2.2	9
252	Epigenetic approaches to overcoming chemotherapy resistance. <i>Lancet Oncology, The</i> , 2015 , 16, 1013-1015	11.7	8
251	PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. <i>Journal of Controlled Release</i> , 2019 , 308, 86-97	11.7	8
250	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 247-257	4.4	8
249	Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017 , 44, 521-536	2.7	8
248	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2017 , 58, 639-645	1.9	8
247	Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. <i>Cancer Biology and Therapy</i> , 2008 , 7, 412-5	4.6	8
246	Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 830, 35-40	3.2	8
245	A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. <i>Biomedical Chromatography</i> , 2002 , 16, 379-82	1.7	8
244	Antiangiogenesis: a possible treatment option for prostate cancer?. <i>Clinical Genitourinary Cancer</i> , 2005 , 4, 197-202	3.3	8
243	National Cancer Institute intramural approach to advanced prostate cancer. <i>Clinical Prostate Cancer</i> , 2002 , 1, 153-62		8
242	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. <i>Blood</i> , 2021 , 137, 896-907	2.2	8
241	Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 374, 438-451	4.7	7
240	Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids. <i>ChemMedChem</i> , 2016 , 11, 2621-2629	3.7	7
239	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. <i>Clinical and Translational Oncology</i> , 2016 , 18, 653-9	3.6	7
238	Precision medicine applications in prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918776920	5.4	7
237	Pharmacologic biomarkers in the development of stratified cancer medicine. <i>Clinical Cancer Research</i> , 2014 , 20, 2525-9	12.9	7

236	Vertebrate embryos as tools for anti-angiogenic drug screening and function. <i>Reproductive Toxicology</i> , 2017 , 70, 49-59	3.4	7
235	A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting. <i>Cancer Biology and Therapy</i> , 2010 , 9, 583-4	4.6	7
234	Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998 , 26, 673-87		7
233	Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. <i>Anti-Cancer Drugs</i> , 2006 , 17, 977-83	2.4	7
232	The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 1-8	6.1	7
231	Mutations in the EGFR: the importance of genotyping. <i>Cancer Biology and Therapy</i> , 2004 , 3, 434-5	4.6	7
230	Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. <i>Acta Oncologica</i> , 1996 , 35, 763-5	3.2	7
229	Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. <i>American Journal of Hematology</i> , 1996 , 51, 152-7	7.1	7
228	A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetyl-Glutamine, by Reversed-Phase, High Performance Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1994 , 17, 2895-2900		7
227	In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. <i>Anti-Cancer Drugs</i> , 1994 , 5, 336-42	2.4	7
226	Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).. <i>Blood</i> , 2008 , 112, 1568-1568	2.2	7
225	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15786-e15786	2.2	7
224	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 176-176	2.2	7
223	Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. <i>Oncotarget</i> , 2019 , 10, 2855-2868	3.3	7
222	Synthesis of a stable and orally bioavailable englerin analogue. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 2641-4	2.9	7
221	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 258-267.e1	3.3	6
220	A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1086, 56-62	3.2	6
219	Revisiting 5 α -reductase inhibitors and the risk of prostate cancer. <i>Nature Reviews Urology</i> , 2018 , 15, 400-403	3.3	6

218	Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 970, 95-101	3.2	6
217	Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. <i>Urology</i> , 2014 , 84, 127-31	1.6	6
216	A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 927, 142-6	3.2	6
215	Uncovering the genetic landscape driving castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2013 , 14, 399-400	4.6	6
214	Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. <i>Cancer Biology and Therapy</i> , 2010 , 10, 1233-4	4.6	6
213	A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1800-5	4.6	6
212	Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. <i>American Journal of Therapeutics</i> , 2010 , 17, 176-81	1	6
211	Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. <i>Biopharmaceutics and Drug Disposition</i> , 1997 , 18, 347-59	1.7	6
210	Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial. <i>Urology</i> , 2008 , 71, 967-70	1.6	6
209	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. <i>BJU International</i> , 2007 , 99, 525-8	5.6	6
208	Antiangiogenesis therapeutic strategies in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2002 , 21, 93-106	9.6	6
207	The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. <i>Oncology Issues</i> , 2000 , 15, 23-27	0.2	6
206	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. <i>Blood</i> , 2020 , 136, 43-45	2.2	6
205	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 314-314	2.2	6
204	Determination of fraction unbound docetaxel using microequilibrium dialysis. <i>Analytical Biochemistry</i> , 2004 , 331, 192-4	3.1	6
203	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 181, 113073	3.5	6
202	Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 827-830	3.5	6
201	Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs. <i>FASEB Journal</i> , 2020 , 34, 11395-11404	0.9	6

200	Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2308-2318	6.1	6
199	Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat. <i>ChemMedChem</i> , 2021 , 16, 2082-2088	3.7	6
198	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1171, 122641	3.2	6
197	Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?. <i>Cancer Biology and Therapy</i> , 2020 , 21, 1-3	4.6	6
196	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	6
195	Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 915-924	6.1	6
194	Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors. <i>MedChemComm</i> , 2019 , 10, 500-504	5	5
193	Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. <i>Urology</i> , 2015 , 85, 616-20	1.6	5
192	Effect of 5 α -Reductase Inhibitor Use on Mortality From Prostate Cancer. <i>JAMA Oncology</i> , 2015 , 1, 321-2	13.4	5
191	Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?. <i>BMJ Open</i> , 2013 , 3,	3	5
190	Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E4820	11.5	5
189	Prostate cancer genomic signature offers prognostic value. <i>Cancer Biology and Therapy</i> , 2010 , 10, 1079-806	4	5
188	Reversal of docetaxel resistance with bevacizumab and thalidomide. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E37-8	3.3	5
187	Randomized discontinuation trial of sorafenib (BAY 43-9006). <i>Cancer Biology and Therapy</i> , 2006 , 5, 1270-2	4.6	5
186	Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2006 , 4, 331-344		5
185	Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 809, 81-6	3.2	5
184	Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.. <i>Blood</i> , 2006 , 108, 2469-2469	2.2	5
183	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 207-207	2.2	5

182	A modeling and simulation study of less frequent dosing of nivolumab 480 mg.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3115-3115	2.2	5
181	A Chiral Pool Approach toward the Synthesis of Thalidomide Metabolites. <i>Heterocycles</i> , 2006 , 70, 321	0.8	5
180	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. <i>Cancer Biology and Therapy</i> , 2020 , 21, 223-230	4.6	5
179	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. <i>Oncologist</i> , 2021 , 26, 288-e541	5.7	5
178	Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 1003-1007	3.5	5
177	A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 565-570	3.5	5
176	Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. <i>Oncology Reports</i> , 2006 , 15, 519-24	3.5	5
175	Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. <i>American Journal of Kidney Diseases</i> , 2017 , 69, 553-554	7.4	4
174	Cellular identity crisis: Antiandrogen resistance by lineage plasticity. <i>Cancer Biology and Therapy</i> , 2017 , 18, 841-842	4.6	4
173	Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 165-175	3.5	4
172	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , 2019 , 14, e0212097	3.7	4
171	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. <i>Molecules</i> , 2020 , 25,	4.8	4
170	CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos. <i>Journal of Anatomy</i> , 2018 , 232, 568-574	2.9	4
169	The canSAR data hub for drug discovery. <i>Lancet Oncology, The</i> , 2016 , 17, 286	21.7	4
168	Multiparametric magnetic resonance imaging of the prostate aids detect lesion progression. <i>Journal of Computer Assisted Tomography</i> , 2014 , 38, 565-7	2.2	4
167	Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. <i>Investigational New Drugs</i> , 2012 , 30, 90-7	4.3	4
166	Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. <i>Cancer Biology and Therapy</i> , 2017 , 18, 470-472	4.6	4
165	Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 355-9	3.2	4

164	Significant addition to treatment options for bone metastasis in prostate cancer. <i>Cancer Biology and Therapy</i> , 2012 , 13, 69-70	4.6	4
163	Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1374-5	4.6	4
162	Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1386-7	4.6	4
161	Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 858, 302-6	3.2	4
160	The role of drug-metabolising enzymes in clinical responses to chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 17-25	5.5	4
159	Leptomeningeal carcinomatosis in metastatic prostate cancer. <i>Southern Medical Journal</i> , 2002 , 95, 107-80.6	4	
158	Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study. <i>Blood</i> , 2014 , 124, 4746-4746	2.2	4
157	Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study. <i>Blood</i> , 2016 , 128, 1507-1507	2.2	4
156	Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures. <i>Molecular Cancer Research</i> , 2020 , 18, 1278-1289	6.6	4
155	Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. <i>Separations</i> , 2016 , 3,	3.1	4
154	Building a hit list for the fight against metastatic castration resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2016 , 17, 231-2	4.6	4
153	Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2019 , 30, 19-22	2.4	4
152	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. <i>Cancer Research</i> , 2021 , 81, 1076-1086	10.1	4
151	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk. <i>Journal of Human Genetics</i> , 2019 , 64, 545-550	4.3	3
150	Targeted PI3K inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma. <i>Cancer Biology and Therapy</i> , 2015 , 16, 204-6	4.6	3
149	Evaluating immune responses after sipuleucel-T therapy. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1119-21	4.6	3
148	Stem cell clinics: risk of proliferation. <i>Lancet Oncology, The</i> , 2020 , 21, 205-206	21.7	3
147	Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?. <i>Cancer Biology and Therapy</i> , 2016 , 17, 467-9	4.6	3

146	Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides. <i>ChemMedChem</i> , 2018 , 13, 2080-2089	3.7	3
145	Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1293-5	4.6	3
144	Androgen receptor sequence and variations in several common prostate cancer cell lines. <i>Cancer Biology and Therapy</i> , 2010 , 9, 383-8	4.6	3
143	Survivin is not induced by novel taxanes. <i>Molecular Pharmaceutics</i> , 2010 , 7, 2216-23	5.6	3
142	shRNA technology: investigating Ras-dependent cancer. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1798-9	4.6	3
141	An Optimized Method for the quantitation of Carboxyamidotriazole (CAI) in Human Plasma with Solid Phase Extraction and reversed Phase HPLC. <i>Analytical Letters</i> , 1997 , 30, 2009-2021	2.2	3
140	Genetic stability of tumor microenvironment. <i>Cancer Biology and Therapy</i> , 2008 , 7, 331-2	4.6	3
139	Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1443-4	4.6	3
138	Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.. <i>Blood</i> , 2005 , 106, 1102-1102	2.2	3
137	Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 64-64	2.2	3
136	A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11540-11540	2.2	3
135	PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 105-105	2.2	3
134	Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. <i>Anticancer Research</i> , 2012 , 32, 2391-8	2.3	3
133	Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. <i>Current Pharmaceutical Biotechnology</i> , 2015 , 16, 553-63	2.6	3
132	Association Between Thiopurine S-Methyltransferase () Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2018 , 23, 106-110	1.6	3
131	Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. <i>Prostate</i> , 2020 , 80, 336-344	4.2	3
130	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 475-486	3.5	3
129	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. <i>Clinical Cancer Research</i> , 2021 , 27, 3298-3306	12.9	3

128	Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa005	0.9	3
127	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021 , 127, 435-444	5.6	3
126	Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1558-1569	6.1	3
125	Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. <i>Science Translational Medicine</i> , 2021 , 13, eabd8077	17.5	3
124	Insulin potentiation therapy for cancer?. <i>Lancet Oncology, The</i> , 2019 , 20, 191-192	21.7	2
123	Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. <i>Pharmacogenomics</i> , 2016 , 17, 1979-1986	2.6	2
122	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 759-770	3.5	2
121	BCRP (ABCG2) 2013 , 311-343		2
120	Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients. <i>Cancer Biology and Therapy</i> , 2017 , 18, 545-546	4.6	2
119	Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1117-9	4.6	2
118	Potential novel role of bevacizumab in glioblastoma and cervical cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1296-8	4.6	2
117	Genetic variant associated with aggressive not indolent prostate cancer. <i>Cancer Biology and Therapy</i> , 2010 , 9, 957-8	4.6	2
116	Androgen synthesis and steroid transporters in prostate cancer: rethinking the transition to CRPC. <i>Cancer Biology and Therapy</i> , 2010 , 9, 1043-5	4.6	2
115	Private Practice Administrative Costs Influenced by Insurance Payer Mix. <i>Journal of Oncology Practice</i> , 2009 , 5, 291-297	3.1	2
114	Reply to C. Nabhan et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e147-e147	2.2	2
113	Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2012 , 13, 237-8	4.6	2
112	Upregulation of the androgen receptor during prostate cancer progression. <i>Cancer Biology and Therapy</i> , 2004 , 3, 284-5	4.6	2
111	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. <i>Blood</i> , 2019 , 133, 1257-1257	2.2	2

110	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10588-10588	2.2	2
109	A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 173-173	2.2	2
108	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11552-11552	2.2	2
107	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors 2021 , 9,		2
106	Author response: Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates 2019 ,		2
105	Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV. <i>Blood</i> , 2019 , 134, 4096-4096	2.2	2
104	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer 2021 , 9,		2
103	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. <i>Cancers</i> , 2021 , 13,	6.6	2
102	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3051-3051	2.2	2
101	Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. <i>Vox Sanguinis</i> , 2021 , 116, 141-154	3.1	2
100	Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in. <i>Pharmacogenomics</i> , 2021 , 22, 81-85	2.6	2
99	On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. <i>Biochemical and Biophysical Research Communications</i> , 2021 , 534, 67-72	3.4	2
98	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29282	3	2
97	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclox-induced cytotoxicity in atypical teratoid/rhabdoid tumors.. <i>Cell Death and Disease</i> , 2022 , 13, 410	9.8	2
96	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 215-218	3.5	1
95	Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2017 , 18, 203-204	4.6	1
94	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 217-221	3.5	1
93	Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime?. <i>BJU International</i> , 2019 , 124, 549-550	5.6	1

92	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
91	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. <i>Scientific Reports</i> , 2019 , 9, 14884	4.9	1
90	A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 942-943, 107-12	3.2	1
89	New mechanism of lenalidomide activity. <i>Cancer Biology and Therapy</i> , 2014 , 15, 968-9	4.6	1
88	The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples. <i>Cancer Biology and Therapy</i> , 2014 , 15, 16-8	4.6	1
87	Preformulation study of NSC-726796. <i>AAPS PharmSciTech</i> , 2012 , 13, 661-73	3.9	1
86	Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism. <i>Cancer Biology and Therapy</i> , 2010 , 9, 163-5	4.6	1
85	A genomic strategy for predicting androgen receptor activity in prostate tumors. <i>Cancer Biology and Therapy</i> , 2009 , 8, 2002-3	4.6	1
84	Aflibercept in pediatric solid tumors: moving beyond the trap. <i>Clinical Cancer Research</i> , 2012 , 18, 4868-71	12.9	1
83	How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1141-2	4.6	1
82	Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 3187-92	3.2	1
81	Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1180-1	4.6	1
80	Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics. <i>Cancer Biology and Therapy</i> , 2006 , 5, 840-1	4.6	1
79	Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation. <i>Current Cancer Therapy Reviews</i> , 2006 , 2, 223-229	0.4	1
78	The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1094-5	4.6	1
77	hTert-Immortalized Endothelial Cells: An Important New Research Tool. <i>Cell Cycle</i> , 2004 , 3, 787-787	4.7	1
76	Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 805, 135-40	3.2	1
75	Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report. <i>Prostate Journal</i> , 1999 , 1, 99-102		1

74	Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome.. <i>Cancer Biology and Therapy</i> , 2022 , 23, 136-138	4.6	1
73	Single whole genome sequencing analysis blazes the trail for precision medicine.. <i>Cancer Biology and Therapy</i> , 2022 , 23, 134-135	4.6	1
72	Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014 , 124, 2080-2080	2.2	1
71	Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2016 , 128, 3339-3339	2.2	1
70	Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4671-4671	2.2	1
69	Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 241-241	2.2	1
68	Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2021 , 9, 189-193	1.6	1
67	Dose Optimization of Pembrolizumab: Less May Be More. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	1
66	Ibrutinib's off-target mechanism: cause for dose optimization. <i>Cancer Biology and Therapy</i> , 2021 , 1-3	4.6	1
65	A Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose De-Escalation. <i>Journal of Clinical Pharmacology</i> , 2021 ,	2.9	1
64	Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3553-3553	2.2	1
63	Flow Rate and Apparent Volume of Cerebrospinal Fluid in Rhesus Macaques () Based on the Pharmacokinetics of Intrathecally Administered Inulin. <i>Comparative Medicine</i> , 2020 , 70, 526-531	1.6	1
62	Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 128-128	2.2	1
61	A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS5095-TPS5095	2.2	1
60	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4543-4543	2.2	1
59	Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. <i>Photochemistry and Photobiology</i> , 2020 , 96, 668-679	3.6	1
58	Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa. <i>AIDS Reviews</i> , 2020 , 23, 13-27	1.5	1
57	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e17044-e17044	2.2	1

56	Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. <i>Scientific Reports</i> , 2021 , 11, 10765	4.9	1
55	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4599-TPS4599	2.2	1
54	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5096-TPS5096	2.2	1
53	Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics. <i>Cancer Biology and Therapy</i> , 2018 , 19, 953-955	4.6	1
52	Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance. <i>Cancer Biology and Therapy</i> , 2018 , 19, 869-870	4.6	1
51	The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?. <i>Lancet Oncology, The</i> , 2021 , 22, 915-916	21.7	1
50	Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer. <i>Oncologist</i> , 2021 , 26, 729-e1493	5.7	1
49	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. <i>JAMA Oncology</i> , 2021 , 7, 1678-1685	13.4	1
48	Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model. <i>Molecular Cancer Research</i> , 2021 , 19, 2081-2095	6.6	1
47	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva 2000 , 14, 338		1
46	Whole or Partial Vessel Outgrowth Assays105-121		1
45	Lutetium-177-PSMA-617: A Vision of the Future.. <i>Cancer Biology and Therapy</i> , 2022 , 23, 186-190	4.6	1
44	Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 130-130	2.2	1
43	Subcutaneous Atezolizumab: A Jab Without a Benefit.. <i>Clinical Pharmacology in Drug Development</i> , 2021 ,	2.3	1
42	Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier. <i>Clinical Cancer Research</i> , 2017 , 23, 7437-7439	12.9	0
41	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.. <i>Oncologist</i> , 2022 , 27, e273-e285	5.7	0
40	Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition. <i>ACS Medicinal Chemistry Letters</i> , 2020 , 11, 1711-1716	4.3	0
39	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2020 , 21, 884-887	4.6	0

38	Facebook groups for alternative treatments for cancer: advertising masquerading as community support. <i>Lancet Oncology, The</i> , 2021 , 22, 25-26	21.7	○
37	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 93-93	2.2	○
36	A new predictive tool for postoperative radiotherapy in prostate cancer. <i>Cancer Biology and Therapy</i> , 2017 , 18, 277-278	4.6	
35	Resisting resistance: Establishing new treatment options for CRPC patients. <i>Cancer Biology and Therapy</i> , 2016 , 17, 337-8	4.6	
34	How do you take your coffee?. <i>Lancet Oncology, The</i> , 2019 , 20, 913-914	21.7	
33	Challenges in overcoming hormonal resistance in prostate cancer. <i>Clinical Investigation</i> , 2014 , 4, 153-162		
32	A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 132, 223-226	3.5	
31	New bigenic mouse model increases the understanding of genetic synergism in the progression of prostate cancer. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1702-3	4.6	
30	Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , 2015 , 16, 201-3	4.6	
29	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. <i>BJU International</i> , 2007 , 100, 1245-8	5.6	
28	DNA microarrays: tissue removal and processing affects gene expression. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1608-9	4.6	
27	Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients. <i>Cancer Biology and Therapy</i> , 2007 , 6, 318-9	4.6	
26	Epidemiology of drug interactions in cancer patients. <i>Nature Reviews Cancer</i> , 2006 , 6, 824-824	31.3	
25	Nitrate tolerance: does tid isosorbide dinitrate mean dosing every eight hours?. <i>DICP: the Annals of Pharmacotherapy</i> , 1991 , 25, 1272-3		
24	Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Blood</i> , 2020 , 136, 18-19	2.2	
23	BETting on next-generation bromodomain inhibitors. <i>American Journal of Clinical and Experimental Urology</i> , 2020 , 8, 129-132	1.6	
22	A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy. <i>Blood</i> , 2021 , 138, 2457-2457	2.2	
21	Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Blood</i> , 2021 , 138, 1815-1815	2.2	

20	Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.. <i>Blood</i> , 2004 , 104, 2406-2406	2.2
19	A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS11586-TPS11586	2.2
18	Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16554-e16554	2.2
17	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5074-5074	2.2
16	Development of a CYP1B1*3 genotyping assay and mechanism of action studies related to docetaxel treatment in CRPC.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16036-e16036	2.2
15	Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects. <i>Blood</i> , 2014 , 124, 3476-3476	2.2
14	Tremelimumab: A monoclonal antibody against CTLA-4 in combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 88-88	2.2
13	Disruption of the HIF-1 α /p300 interaction as a means of inhibiting angiogenesis. <i>FASEB Journal</i> , 2012 , 26, 613.3	0.9
12	Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3042-3042	2.2
11	TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 211-211	2.2
10	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 218-218	2.2
9	Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. <i>Cancer Biology and Therapy</i> , 2020 , 21, 782-784	4.6
8	Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. <i>Scientific Reports</i> , 2021 , 11, 5662	4.9
7	A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5090-TPS5090	2.2
6	YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?. <i>Cancer Biology and Therapy</i> , 2016 , 17, 592-4	4.6
5	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , 2018 , 19, 97-100	4.6
4	Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32. <i>Drug Metabolism Letters</i> , 2018 , 12, 153	2.1
3	Prostate cancer - 6th International Congress. <i>IDrugs: the Investigational Drugs Journal</i> , 2006 , 9, 675-8	

2 ABCG2, THE BREAST CANCER RESISTANCE PROTEIN (BCRP) **2022**, 235-256

1 Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application.. *Journal of Pharmaceutical and Biomedical Analysis*, **2022**, 213, 114685

3.5